Cargando…
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. Ho...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603894/ https://www.ncbi.nlm.nih.gov/pubmed/36293504 http://dx.doi.org/10.3390/ijms232012647 |
_version_ | 1784817671219445760 |
---|---|
author | Wang, Gongwei Liu, Ying Liu, Shuoru Lin, Yuan Hu, Cheng |
author_facet | Wang, Gongwei Liu, Ying Liu, Shuoru Lin, Yuan Hu, Cheng |
author_sort | Wang, Gongwei |
collection | PubMed |
description | As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. However, as the cancer progresses, the effectiveness of treatment options gradually decreases, especially in metastatic castration-resistant prostate cancer (mCRPC), for which there are fewer therapeutic options and which have a shorter survival period and worse prognosis. For this reason, oncolytic viral therapy (PV), with its exceptional properties of selective tumor killing, relatively good safety in humans, and potential for transgenic delivery, has attracted increasing attention as a new form of anti-tumor strategy for PCa. There is growing evidence that OV not only kills tumor cells directly by lysis but can also activate anticancer immunity by acting on the tumor microenvironment (TME), thereby preventing tumor growth. In fact, evidence of the efficacy of this strategy has been observed since the late 19th century. However, subsequently, interest waned. The renewed interest in this therapy was due to advances in biotechnological methods and innovations at the end of the 20th century, which was also the beginning of PCa therapy with OV. Moreover, in combination with chemotherapy, radiotherapy, gene therapy or immunotherapy, OV viruses can have a wide range of applications and can provide an effective therapeutic result in the treatment of PCa. |
format | Online Article Text |
id | pubmed-9603894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96038942022-10-27 Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter Wang, Gongwei Liu, Ying Liu, Shuoru Lin, Yuan Hu, Cheng Int J Mol Sci Review As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. However, as the cancer progresses, the effectiveness of treatment options gradually decreases, especially in metastatic castration-resistant prostate cancer (mCRPC), for which there are fewer therapeutic options and which have a shorter survival period and worse prognosis. For this reason, oncolytic viral therapy (PV), with its exceptional properties of selective tumor killing, relatively good safety in humans, and potential for transgenic delivery, has attracted increasing attention as a new form of anti-tumor strategy for PCa. There is growing evidence that OV not only kills tumor cells directly by lysis but can also activate anticancer immunity by acting on the tumor microenvironment (TME), thereby preventing tumor growth. In fact, evidence of the efficacy of this strategy has been observed since the late 19th century. However, subsequently, interest waned. The renewed interest in this therapy was due to advances in biotechnological methods and innovations at the end of the 20th century, which was also the beginning of PCa therapy with OV. Moreover, in combination with chemotherapy, radiotherapy, gene therapy or immunotherapy, OV viruses can have a wide range of applications and can provide an effective therapeutic result in the treatment of PCa. MDPI 2022-10-21 /pmc/articles/PMC9603894/ /pubmed/36293504 http://dx.doi.org/10.3390/ijms232012647 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wang, Gongwei Liu, Ying Liu, Shuoru Lin, Yuan Hu, Cheng Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title | Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title_full | Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title_fullStr | Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title_full_unstemmed | Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title_short | Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter |
title_sort | oncolyic virotherapy for prostate cancer: lighting a fire in winter |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603894/ https://www.ncbi.nlm.nih.gov/pubmed/36293504 http://dx.doi.org/10.3390/ijms232012647 |
work_keys_str_mv | AT wanggongwei oncolyicvirotherapyforprostatecancerlightingafireinwinter AT liuying oncolyicvirotherapyforprostatecancerlightingafireinwinter AT liushuoru oncolyicvirotherapyforprostatecancerlightingafireinwinter AT linyuan oncolyicvirotherapyforprostatecancerlightingafireinwinter AT hucheng oncolyicvirotherapyforprostatecancerlightingafireinwinter |